Lou et al. [27] examined records from 184 APL patients who were treated with ATRA+ATO and found that there was no association between the 3-year relapse-free survival (RFS) rate and presenting WBC counts, FLT3-ITD status, or PML/RARA isoforms. This evidence concerns the gene PML and acute promyelocytic leukemia.